Home » Stocks » OCDX

Ortho Clinical Diagnostics Holdings plc (OCDX)

Stock Price: $20.75 USD -0.52 (-2.44%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 4.62B
Revenue (ttm) 1.77B
Net Income (ttm) -211.90M
Shares Out 222.58M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE 30.77
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $20.75
Previous Close $21.27
Change ($) -0.52
Change (%) -2.44%
Day's Open 20.95
Day's Range 20.74 - 21.49
Day's Volume 615,315
52-Week Range 15.14 - 21.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 2021 Guidance First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 20...

1 week ago - GlobeNewsWire

- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization o...

1 week ago - PRNewsWire

ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics compani...

1 week ago - PRNewsWire

RARITAN, N.J., April 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious...

2 weeks ago - PRNewsWire

RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results f...

3 weeks ago - GlobeNewsWire

RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for i...

4 weeks ago - PRNewsWire

- The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months  RARITAN, N.J., M...

1 month ago - PRNewsWire

RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization fr...

1 month ago - PRNewsWire

Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%

1 month ago - GlobeNewsWire

Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%

1 month ago - GlobeNewsWire

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

Other stocks mentioned: BOLT, MASS, MDWT, NEXI
2 months ago - 24/7 Wall Street

RARITAN, N.J., March 8, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies dedicated to transforming patient care, today announced that it...

2 months ago - PRNewsWire

RARITAN, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transform...

2 months ago - GlobeNewsWire

Former CEO of Charles Schwab Investment Management will also serve as audit committee chair Former CEO of Charles Schwab Investment Management will also serve as audit committee chair

2 months ago - GlobeNewsWire

Agencies Provide Stable Outlook Following Company's Initial Public Offering Agencies Provide Stable Outlook Following Company's Initial Public Offering

2 months ago - GlobeNewsWire

Increases facility by $150 million and extends it to 2026

3 months ago - GlobeNewsWire

RARITAN, N.J., Feb. 4, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving...

3 months ago - PRNewsWire

After its shares fell nearly 7% in a public debut last week, Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) is clawing its way back to a modicum of respectability. The Raritan, New Jersey-based c...

3 months ago - GuruFocus

RARITAN, N.J., Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through...

3 months ago - PRNewsWire

Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving...

3 months ago - PRNewswire

Ortho Clinical Diagnostics, a Carlyle-backed global provider of in vitro diagnostic products, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, this is lik...

4 months ago - NASDAQ

Ortho Clinical Diagnostics Holdings plc has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About OCDX

Ortho Clinical Diagnostics is a pure-play in vitro diagnostics (“IVD”) business driven by our credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides our priorities as an organization. As a leader in IVD, we impact approximately 800,000 patients every day. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communitie... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jan 28, 2021
CEO
Chris Smith
Employees
4,500
Stock Exchange
NASDAQ
Ticker Symbol
OCDX
Full Company Profile

Financial Performance

In 2020, OCDX's revenue was $1.77 billion, a decrease of -1.96% compared to the previous year's $1.80 billion. Losses were -$211.90 million, 35.1% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for OCDX is 24.45, which is an increase of 17.83% from the latest price.

Price Target
$24.45
(17.83% upside)